Results 201 to 210 of about 19,239,566 (385)

Representation of the solar capacity value in the ReEDS capacity expansion model

open access: yesPhotovoltaic Specialists Conference, 2014
B. Sigrin   +3 more
semanticscholar   +1 more source

Building research capacity: the value of conferences

open access: yesInternational Journal of Pharmacy Practice, 2016
Parastou, Donyai, Matthew J, Boyd
openaire   +2 more sources

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

Development of a novel method to evaluate gingivitis in children by combining rapid saliva test systems. [PDF]

open access: yesSci Rep
Iwamoto Y   +15 more
europepmc   +1 more source

Comparing resource adequacy metrics and their influence on capacity value

open access: yesIEEE International Conference on Probabilistic Methods Applied to Power Systems, 2014
E. Ibanez, M. Milligan
semanticscholar   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy